Aktiechat - investeringstips

	11/5 16:09 af bibob	Mr Winkel. Can you tell us the % of royalty you get from Teprutumumab. ?
	11/5 16:09 af Jan Van de Winkel	future milestones could be triggered by clinical progress in daratumumab development as well as sales milestones.
	11/5 16:09 af Jan Van de Winkel	The first milestone has just been achieved with the approval of daratumumab in Europe in second line MM (48 mn USD)....approx. 325 mn DKK...
	11/5 16:08 af Helge Larsen/PI-redaktør	Bikube: “800 million are expected in milestones. What events trigger these”?
	11/5 16:07 af Jan Van de Winkel	the most significant tier, is that when sales exceed 3 bn USD, the royalty rate to Genmab will be 20%.
	11/5 16:07 af Jan Van de Winkel	Current royalty is at 12 percent royalty tranche and we expect to step up one tier this year....
	11/5 16:06 af kkjoel	Reg. dara royalty-levels: will you down the line, as the various thresholds are exceeded, inform the marked THAT they were exceeded and HOW MUCH the next royalty-%-step is? Or are we for ever destined to guess (which probably WILL come v close to facts).. based on JnJ turnover, approximate dollar-exchange rates, and GENs royalty-income?
	11/5 16:05 af Jan Van de Winkel	Expenses 1 bn DKK leading to operating Income of 1 bn DKK, cash greater than 4.5 bn DKK.
	11/5 16:05 af Jan Van de Winkel	Revenue guidance for 2017 is around 2 bn DKK....
	11/5 16:04 af Helge Larsen/PI-redaktør	Can you tell us about your guiding for 2017?
	11/5 16:04 af Jan Van de Winkel	and approval in important second line MM in Europe, and 48 mn USD milestone.
	11/5 16:03 af Jan Van de Winkel	Exciting new trials BMS Opdivo, Tecentriq NSCLC, RRMM Dara + POM + d (Apollo), and the start of the Amgen RRMM Dara plus Krypolis + d....
	11/5 16:02 af Jan Van de Winkel	up 28 percent to Q4 2016. Launched in 18 EU countries and US...
	11/5 16:02 af Jan Van de Winkel	DARZALEX Janssen net sales 255 mn USD....
	11/5 16:01 af Jan Van de Winkel	cash position 4.8 bn DKK....a great start to the year. Important events ...
	11/5 16:01 af Jan Van de Winkel	revenue growth exceeded expense increase equaling an increase in operating income of 30 mn DKK to 46 mn DKK for Q1....
	11/5 16:00 af Jan Van de Winkel	expenses up 33 percent, driven by the investment in our pipeline of products....
	11/5 16:00 af Jan Van de Winkel	Revenues up 48 percent driven by DARZALEX royalty income....
	11/5 16:00 af Jan Van de Winkel	David will start with the financials....
	11/5 16:00 af Helge Larsen/PI-redaktør	Great. First of all let me just congratulate on the great results for Q1 . Can you give us a short-term update on key figures and important events in Q1?
	11/5 15:59 af Jan Van de Winkel	We are eager to go!
	11/5 15:59 af Helge Larsen/PI-redaktør	Jan van de Winkel and David Eatwell. Welcome to Q & A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	11/5 15:58 af Helge Larsen/PI-redaktør	:-)
	11/5 15:57 af Jan Van de Winkel	yes, we are here. Nice to talk to you.

	11/5 15:56 af Helge Larsen/PI-redaktør	Jan and David. Are you online?